{"title":"拓展E3连接酶用于靶向蛋白降解的领域","authors":"Luke T. Kramer , Xiaoyu Zhang","doi":"10.1016/j.crchbi.2022.100020","DOIUrl":null,"url":null,"abstract":"<div><p>Targeted protein degradation (TPD) is a rapidly developing field in chemical biology and drug discovery. Various TPD modalities have emerged, with proteolysis-targeting chimeras (PROTACs) being the most well-developed at present. In PROTACs, a heterobifunctional molecule is used to recruit an E3 ligase to degrade a protein of therapeutic interest. Most of the PROTAC candidates that have been developed thus far use either CRBN or VHL as the hijacked E3 ligase, which poses several limitations. In order to overcome these limitations and furthermore realize the full potential of TPD as a therapeutic modality, the field will need to unlock additional E3 ligases. This review will therefore present 11 alternative E3 ligases for TPD. It will also describe some of the ongoing platform development that is facilitating the discovery of additional E3 ligases for TPD.</p></div>","PeriodicalId":72747,"journal":{"name":"Current research in chemical biology","volume":"2 ","pages":"Article 100020"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666246922000027/pdfft?md5=b47489fa81c27f4b2effa1a8625d50e0&pid=1-s2.0-S2666246922000027-main.pdf","citationCount":"20","resultStr":"{\"title\":\"Expanding the landscape of E3 ligases for targeted protein degradation\",\"authors\":\"Luke T. Kramer , Xiaoyu Zhang\",\"doi\":\"10.1016/j.crchbi.2022.100020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Targeted protein degradation (TPD) is a rapidly developing field in chemical biology and drug discovery. Various TPD modalities have emerged, with proteolysis-targeting chimeras (PROTACs) being the most well-developed at present. In PROTACs, a heterobifunctional molecule is used to recruit an E3 ligase to degrade a protein of therapeutic interest. Most of the PROTAC candidates that have been developed thus far use either CRBN or VHL as the hijacked E3 ligase, which poses several limitations. In order to overcome these limitations and furthermore realize the full potential of TPD as a therapeutic modality, the field will need to unlock additional E3 ligases. This review will therefore present 11 alternative E3 ligases for TPD. It will also describe some of the ongoing platform development that is facilitating the discovery of additional E3 ligases for TPD.</p></div>\",\"PeriodicalId\":72747,\"journal\":{\"name\":\"Current research in chemical biology\",\"volume\":\"2 \",\"pages\":\"Article 100020\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666246922000027/pdfft?md5=b47489fa81c27f4b2effa1a8625d50e0&pid=1-s2.0-S2666246922000027-main.pdf\",\"citationCount\":\"20\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current research in chemical biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666246922000027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current research in chemical biology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666246922000027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 20
摘要
靶向蛋白降解(Targeted protein degradation, TPD)是化学生物学和药物发现领域中一个快速发展的领域。多种TPD模式已经出现,以蛋白水解靶向嵌合体(proteolysis-targeting chimeras, PROTACs)是目前发展最为完善的。在PROTACs中,使用异双功能分子招募E3连接酶来降解治疗感兴趣的蛋白质。迄今为止开发的大多数PROTAC候选药物使用CRBN或VHL作为劫持的E3连接酶,这存在一些局限性。为了克服这些限制,进一步实现TPD作为一种治疗方式的全部潜力,该领域将需要解锁额外的E3连接。因此,本综述将提出11种用于TPD的替代E3连接。它还将描述一些正在进行的平台开发,这些开发有助于发现用于TPD的其他E3连接。
Expanding the landscape of E3 ligases for targeted protein degradation
Targeted protein degradation (TPD) is a rapidly developing field in chemical biology and drug discovery. Various TPD modalities have emerged, with proteolysis-targeting chimeras (PROTACs) being the most well-developed at present. In PROTACs, a heterobifunctional molecule is used to recruit an E3 ligase to degrade a protein of therapeutic interest. Most of the PROTAC candidates that have been developed thus far use either CRBN or VHL as the hijacked E3 ligase, which poses several limitations. In order to overcome these limitations and furthermore realize the full potential of TPD as a therapeutic modality, the field will need to unlock additional E3 ligases. This review will therefore present 11 alternative E3 ligases for TPD. It will also describe some of the ongoing platform development that is facilitating the discovery of additional E3 ligases for TPD.